Back to top
more

NextCure (NXTC)

(Delayed Data from NSDQ)

$1.53 USD

1.53
108,827

+0.04 (2.68%)

Updated May 3, 2024 04:00 PM ET

After-Market: $1.53 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing

NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

NextCure (NXTC) Down on Shelving Plans to Develop Candidate

NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.

All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy

NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade

NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NextCure (NXTC) in Focus: Stock Moves 7.6% Higher

NextCure (NXTC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Will NextCure, Inc. (NXTC) Report Negative Q2 Earnings? What You Should Know

NextCure, Inc. (NXTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NextCure Inc (NXTC) Beats Q1 Earnings and Revenue Estimates

NextCure Inc (NXTC) delivered earnings and revenue surprises of 156.90% and 1621.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Why You Shouldn't Bet Against NextCure (NXTC) Stock

NextCure (NXTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well